[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651764":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":43,"locations":52,"responsibleParty":65,"collaborators":36,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":36,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":36,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":36,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Federal University of São Paulo","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Platelet-Rich Plasma Plus Ibuprofen","EXPERIMENTAL","Participants will receive a single ultrasound-guided intra-articular injection of leukocyte-rich platelet-rich plasma, followed by ibuprofen 400 mg orally every eight hours for five consecutive days.",[13,14],"Biological: Leukocyte-Rich Platelet-Rich Plasma","Drug: ibuprofen",{"label":16,"type":17,"description":18,"interventionNames":19},"Platelet-Rich Plasma Plus Acetaminophen","ACTIVE_COMPARATOR","Participants will receive a single ultrasound-guided intra-articular injection of leukocyte-rich platelet-rich plasma, followed by acetaminophen 500 mg orally every eight hours for five consecutive days.",[13,20],"Drug: Acetaminophen",[22,31,37],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"BIOLOGICAL","Leukocyte-Rich Platelet-Rich Plasma","A single 12 mL intra-articular injection of autologous leukocyte-rich platelet-rich plasma, prepared from 54 mL of peripheral venous blood using a standardized single-centrifugation protocol without anticoagulants or exogenous activators. The injection will be performed using a lateral suprapatellar approach under ultrasound guidance.",[16,9],[28,29,30],"LR-PRP","Platelet-Rich Plasma","PRP",{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","ibuprofen","Ibuprofen 400 mg oral capsules administered every eight hours for five consecutive days, starting immediately after the platelet-rich plasma injection. Capsules will be visually identical to the acetaminophen capsules.",[9],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Acetaminophen","Acetaminophen 500 mg oral capsules administered every eight hours for five consecutive days, starting immediately after the platelet-rich plasma injection. Capsules will be visually identical to the ibuprofen capsules.",[16],[42],"Paracetamol",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":36,"email":48},"Guilherme Moury Fernandes, MD","CONTACT","+55 11 3385-4343","guilherme.moury@unifesp.br",{"name":50,"role":46,"phone":47,"phoneExt":36,"email":51},"Monique Ribas Scherer, MD","monique.scherer@unifesp.br",[53],{"facility":54,"status":36,"city":55,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":36},"Disciplina de Medicina Esportiva da UNIFESP","São Paulo","04022-002","Brazil","BR",{"type":60,"coordinates":61},"Point",[62,63],-46.63611,-23.5475,{"lat":63,"lon":62},{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Paulo Santoro Belangero","Affiliated Professor, Department of Orthopaedics and Traumatology","100651764","effect-of-nonsteroidal-anti-inflammatory-drug-restriction-on-the-efficacy-of-platelet-rich-plasma-in-knee-osteoarthritis-100651764",false,"NCT07766330","Effect of Nonsteroidal Anti-Inflammatory Drug Restriction on the Efficacy of Platelet-Rich Plasma in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Knee pain for at least 3 months\n* Radiographic evidence of knee osteoarthritis classified as Kellgren-Lawrence grade I, II, or III\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Body mass index of 35 kg\u002Fm2 or higher\n* Pregnancy or breastfeeding\n* Diabetes mellitus with glycated hemoglobin greater than 6.5%\n* Hematologic disease, including anemia, coagulopathy, or thrombophilia\n* Hemoglobin below 11 g\u002FdL\n* Hematocrit below 33%\n* Platelet count below 150,000\u002Fmm3\n* Advanced knee osteoarthritis\n* Rheumatologic disease\n* Chronic kidney disease\n* Respiratory disease, including rhinitis, asthma, or chronic obstructive pulmonary disease\n* Active or previous oncologic disease, as defined in the protocol\n* Fibromyalgia\n* Psychiatric disorder currently under treatment\n* Substance dependence, including smoking, harmful alcohol use, or other substance use\n* Use of nonsteroidal anti-inflammatory drugs within the previous 30 days\n* Use of systemic, intra-articular, topical, or inhaled glucocorticoids within the previous 3 months\n* Current use of anticoagulant or antiplatelet medication\n* American Society of Anesthesiologists physical status classification of 3 or higher\n* Currently receiving disability or sickness-related social security benefits\n* Inability or unwillingness to provide informed consent or complete the required patient-reported outcome measures","ALL","18 Years","80 Years",{"count":79,"type":80},90,"ESTIMATED","INTERVENTIONAL",[83],"NA","The goal of this randomized clinical trial is to learn whether taking ibuprofen, a nonsteroidal anti-inflammatory drug, after a platelet-rich plasma (PRP) injection changes pain relief and knee function in adults with knee osteoarthritis.\n\nThe main questions it aims to answer are:\n\nDoes ibuprofen change the improvement in knee pain six months after a PRP injection compared with acetaminophen?\n\nDoes ibuprofen change knee function or the need for additional pain medicine during follow-up?\n\nResearchers will compare PRP followed by ibuprofen with PRP followed by acetaminophen. Participants will receive one ultrasound-guided PRP injection and take the assigned medication every eight hours for five days. They will complete assessments of pain, knee function, additional pain medicine use, and safety. Participants and the physician performing the injection will not know which medication was assigned.",[86],"Osteoarthritis, Knee",[29,88,89,90],"Nonsteroidal Anti-Inflammatory Drugs","Intra-Articular Injection","Knee Pain","NOT_YET_RECRUITING","2026-08-11",{"date":94,"type":95},"2026-08-14","ACTUAL",{"date":97,"type":80},"2026-10-01",{"date":99,"type":80},"2028-10",{"name":5,"class":6},1]